Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BBLG Bone Biologics	$2.20 +1.4%	$3.27	$2.08 ▼ $16.50	$3.90M	0.66	45,932 shs	19,252 shs
BIOL BIOLASE		$0.01	$0.02 ▼ $1.94	$581K	0.67	2.58 million shs	2 shs
BJDX Bluejay Diagnostics	$1.39 +3.7%	$1.55	$1.26 ▼ $12.45	$2M	0.48	5.18 million shs	282,097 shs
NAOV Nanovibronix	$5.39 +7.2%	$8.63	$5.00 ▼ $162.50	$1.30M	1.83	46,774 shs	38,441 shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BBLG Bone Biologics	-2.25%	-7.66%	-26.94%	-55.89%	-77.11%
BIOL BIOLASE	0.00%	0.00%	-88.37%	-87.50%	-98.05%
BJDX Bluejay Diagnostics	+3.08%	+2.29%	-14.10%	-25.97%	-89.49%
NAOV Nanovibronix	-6.68%	-25.15%	-45.62%	-55.09%	-92.69%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Earnings & Valuation
BBLG Bone Biologics	0.9131 of 5 stars	0.0	5.0	0.6	1.3
BIOL BIOLASE	0.9385 of 5 stars	3.5	0.0	0.0	0.0
BJDX Bluejay Diagnostics	0.5082 of 5 stars	0.0	3.0	2.2	0.6
NAOV Nanovibronix	0.2643 of 5 stars	0.0	3.0	0.9	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BBLG Bone Biologics	0.00	N/A	N/A	N/A
BIOL BIOLASE	3.00	Buy	$1.20	∞ Upside
BJDX Bluejay Diagnostics	0.00	N/A	N/A	N/A
NAOV Nanovibronix	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BBLG Bone Biologics	N/A	N/A	N/A	N/A	$3.67 per share	N/A
BIOL BIOLASE	$48.83M	0.00	N/A	N/A	($0.07) per share	0.00
BJDX Bluejay Diagnostics	$250K	8.28	N/A	N/A	$3.54 per share	0.39
NAOV Nanovibronix	$2.56M	0.55	N/A	N/A	$156.59 per share	0.03

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BBLG Bone Biologics	-$4.11M	N/A	0.00	N/A	N/A	N/A	-100.58%	-93.31%	N/A
BIOL BIOLASE	-$20.63M	-$14.94	N/A	N/A	N/A	-41.65%	-1,782.73%	-55.31%	N/A
BJDX Bluejay Diagnostics	-$7.72M	-$125.15	N/A	∞	N/A	N/A	-362.07%	-299.10%	N/A
NAOV Nanovibronix	-$3.70M	-$13.53	N/A	∞	N/A	-380.29%	-45.24%	-34.24%	N/A

Latest BIOL, BJDX, NAOV, and BBLG Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/19/2025	Q2 2025	NAOV Nanovibronix	N/A	-$1.03	N/A	-$1.03	N/A	$0.49 million
8/14/2025	Q2 2025	BBLG Bone Biologics	-$0.58	-$1.33	-$0.75	-$1.33	N/A	N/A
8/7/2025	Q2 2025	BJDX Bluejay Diagnostics	N/A	-$1.41	N/A	-$1.41	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BBLG Bone Biologics	N/A	N/A	N/A	N/A	N/A
BIOL BIOLASE	N/A	N/A	N/A	N/A	N/A
BJDX Bluejay Diagnostics	N/A	N/A	N/A	N/A	N/A
NAOV Nanovibronix	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BBLG Bone Biologics	N/A	17.25	12.60
BIOL BIOLASE	N/A	0.71	0.36
BJDX Bluejay Diagnostics	N/A	4.56	4.56
NAOV Nanovibronix	N/A	1.05	0.22

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BBLG Bone Biologics	34.30%
BIOL BIOLASE	8.79%
BJDX Bluejay Diagnostics	18.47%
NAOV Nanovibronix	16.39%

Insider Ownership

Company	Insider Ownership
BBLG Bone Biologics	6.10%
BIOL BIOLASE	0.27%
BJDX Bluejay Diagnostics	0.08%
NAOV Nanovibronix	6.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BBLG Bone Biologics	2	1.80 million	512,000	Not Optionable
BIOL BIOLASE	160	33.41 million	33.32 million	Not Optionable
BJDX Bluejay Diagnostics	9	1.49 million	1.49 million	Not Optionable
NAOV Nanovibronix	20	260,000	242,000	Not Optionable

BIOL, BJDX, NAOV, and BBLG Headlines

Recent News About These Companies

NanoVibronix Delays Q2 2025 10-Q Filing

August 15, 2025 | msn.com

NanoVibronix Inc trading halted, volatility trading pause

August 14, 2025 | msn.com

NanoVibronix announces another reverse stock split

August 8, 2025 | massdevice.com

NanoVibronix Appoints New Executive VP of Finance

August 2, 2025 | theglobeandmail.com

NanoVibronix Secures $8 Million Through Securities Agreement

July 24, 2025 | theglobeandmail.com

NanoVibronix enters into $50M financing agreement

July 18, 2025 | massdevice.com

NanoVibronix adjourns special meeting due to lack of quorum ...

July 12, 2025 | investing.com

NanoVibronix corrects Series G Preferred Stock floor price in charter ...

July 11, 2025 | investing.com

NanoVibronix Announces ENvue Drive – First Intelligent Robotic Platform in Development for Bedside Feeding Tube and Vascular Line Navigation - Morningstar

June 27, 2025 | morningstar.comM

NanoVibronix, Inc. (NAOV) - Yahoo Finance

June 27, 2025 | finance.yahoo.com

NanoVibronix Announces ENvue Drive – First Intelligent Robotic Platform in Development for Bedside Feeding Tube and Vascular Line Navigation

June 26, 2025 | finance.yahoo.com

NanoVibronix has a next-gen robotic system under development

June 26, 2025 | massdevice.com

NanoVibronix's ENvue Medical Division Announces Agreement with New York Medical Center to Implement ENvue™ Navigation Systems for Enteral Feeding Tube Placement

June 24, 2025 | businesswire.com

ENvue Medical Granted U.S. Patent for Pediatric Feeding Tube Guidance System

June 11, 2025 | finance.yahoo.com

NanoVibronix appoints new CEO after acquisition

June 5, 2025 | uk.investing.com

NanoVibronix Appoints Doron Besser As Chief Executive Officer

June 5, 2025 | nasdaq.com

NanoVibronix Replaces CEO, Retail Believes This Was Only A ‘Starter’

June 4, 2025 | msn.com

NanoVibronix Announces CEO Transition

June 4, 2025 | finance.yahoo.com

NanoVibronix refutes false stock offering claims

May 29, 2025 | investing.com

NanoVibronix Responds to False Post

May 28, 2025 | businesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BIOL, BJDX, NAOV, and BBLG Company Descriptions

Bone Biologics NASDAQ:BBLG

$2.20 +0.03 (+1.38%)

Closing price 04:00 PM Eastern

Extended Trading

$2.20 +0.00 (+0.23%)

As of 06:43 PM Eastern

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1. The company's platform technology is used in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.

BIOLASE NASDAQ:BIOL

BIOLASE, Inc., together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications. The company offers Waterlase all-tissue dental laser systems for cutting soft and hard tissues; diode soft-tissue laser systems for soft tissue, hygiene, temporary pain relief, teeth whitening, and cosmetic procedures; and Epic Hygiene laser to manage non-surgical periodontitis and enhance clinical production. It also manufactures and sells consumable products and accessories for its laser systems, as well as markets flexible fibers and hand pieces; and sells teeth whitening gel kits. The company sells its products through its field sales force and distributor network. The company was formerly known as BIOLASE Technology, Inc. and changed its name to BIOLASE, Inc. in 2012. BIOLASE, Inc. was founded in 1984 and is headquartered in Foothill Ranch, California.

Bluejay Diagnostics NASDAQ:BJDX

$1.39 +0.05 (+3.73%)

Closing price 04:00 PM Eastern

Extended Trading

$1.40 +0.01 (+0.72%)

As of 07:54 PM Eastern

Bluejay Diagnostics, Inc., a medical diagnostic company, develops rapid test for the monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge, which includes reagents and components. The company also offers ALLEREYE diagnostic test, a point-of-care device for the diagnosis of allergic conjunctivitis. In addition, it develops IL-6 for the monitoring of disease progression in critical care; as well as hsTNT/I and NT-proBNP for the monitoring of patients acuity with chest pain. The company was incorporated in 2015 and is headquartered in Acton, Massachusetts.

Nanovibronix NASDAQ:NAOV

$5.39 +0.36 (+7.16%)

Closing price 04:00 PM Eastern

Extended Trading

$5.40 +0.00 (+0.09%)

As of 07:35 PM Eastern

NanoVibronix, Inc., through its subsidiary, NanoVibronix Ltd., focuses on the manufacture and sale of noninvasive biological response-activating devices that target biofilm prevention, wound healing, and pain therapy. Its product portfolio includes UroShield, an ultrasound-based product to prevent bacterial colonization and biofilm in urinary catheters, enhance antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use. The company also offers PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures; and WoundShield, a patch-based therapeutic ultrasound device intended to facilitate tissue regeneration and wound healing by using ultrasound to increase local capillary perfusion and tissue oxygenation. It sells its products directly to patients, as well as through distributor agreements in the United States, Israel, Europe, Australia, India, and internationally. The company was incorporated in 2003 and is headquartered in Elmsford, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time